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Abstract
Background and aims
Persistent intestinal damage is associated with higher complication rates in celiac disease.
We aimed to assess the potential modifiers of mucosal recovery.
Materials and methods
We screened databases (PubMed, Embase, Cochrane Trials, and Web of Science) for papers
on celiac disease. Papers discussing (1) celiac patients (2) follow-up biopsy and (3) mucosal
recovery after commencement of a gluten-free diet were included. The primary outcome was
to produce a comprehensive analysis of complete mucosal recovery (i.e., Marsh 0 on follow-
up). We compared children’s recovery ratios to those of adults. Patients following a strict glu-
ten-free dietary regimen were included in a subgroup. Summary point estimates, 95% confi-
dence intervals (CIs), and 95% predictive intervals (PIs) were calculated. Heterogeneity was
tested with I2-statistic. The PROSPERO registration number is CRD42016053482.
Results
The overall complete mucosal recovery ratio, calculated from 37 observational studies, was
0.36 (CI: 0.28–0.44, PI: -0.12–0.84; I2: 98.4%, p<0.01). Children showed higher complete
mucosal recovery ratio than adults (p<0.01): 0.65 (CI: 0.44–0.85, PI: -0.10–1.39; I2: 96.5%,
p<0.01) as opposed to 0.24 (CI: 0.15–0.33, PI: -0.19–1.08; I2: 96.3%, p<0.01). In the strict
dietary adherence subgroup, complete mucosal recovery ratio was 0.47 (CI: 0.24–0.70, PI:
-0.47–1.41; I2: 98.8%, p<0.001). On meta-regression, diagnostic villous atrophy (Marsh 3)
ratio (-8.97, p<0.01) and male ratio (+6.04, p<0.01) proved to be a significant determinant of
complete mucosal recovery, unlike duration of gluten-free diet (+0.01, p = 0.62). The
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correlation between complete mucosal recovery ratio and age on diagnosis is of borderline
significance (-0.03, p = 0.05).
Conclusions
There is considerable heterogeneity across studies concerning complete mucosal recovery
ratios achieved by a gluten-free diet in celiac disease. Several celiac patients fail to achieve
complete mucosal recovery even if a strict dietary regimen is followed. Younger age on diag-
nosis, less severe initial histologic damage and male gender predispose for achieving muco-
sal recovery.
Introduction
Celiac disease is an immune-mediated systemic disorder. It can strike in any age in genetically
susceptible individuals by consuming gluten-containing foods. The pathological reaction to
gluten results in pathognomonic impairment of the small intestinal villous structure [1].
About 1% of the population in the United States and Western Europe is affected [2, 3].
In most patients in whom mucosal recovery cannot be achieved frequently [4], quick and
dramatic improvement in symptoms is expected when switching to a gluten-free diet (GFD)
[5]. Surprisingly, the intestinal mucosal recovery ratio ranges from 0 to 100% across studies [4,
6–68], the hypothesized modifiers are age on diagnosis [6–11, 13, 15, 16, 28, 42, 48, 51], dura-
tion of GFD [7, 9–14, 16, 25, 40, 42, 43, 51, 54], gender [6–13, 16, 69], initial histological sever-
ity [6–9, 11–15, 70], and dietary adherence [6–9, 11–13, 17, 28, 30].
The need for repeated biopsy is a matter of controversy: it is clearly recommended in
patients remaining symptomatic on the long term GFD [71, 72]. However, symptoms [22, 37,
39, 73] and celiac-specific serology [74] correlate poorly with the follow-up histology (i.e., the
degree of mucosal recovery), resulting in the misidentification of the non-recovered, who
might be at higher risk of adverse outcomes in the long run [8, 9, 70, 73, 75, 76]. Intact mucosa
has remained a desirable goal of the therapy.
To date, one meta-analysis related to mucosal recovery has been published, in which the
focal question was the performance of celiac-specific antibody in predicting persistent villous
atrophy, which resulted in a high exclusion rate of relevant articles [74]. Here, we planned to
address the question whether celiac children on a GFD display higher mucosal recovery ratios
than adults. In addition, the following potential modifiers of mucosal recovery were also exam-
ined: age on diagnosis, duration of and adherence to GFD, initial histological severity, and
study quality. Our results might complement the careful selection process of subjects for
whom a follow-up biopsy would be beneficial.
Materials and methods
This meta-analysis was conducted and reported following the guidelines proposed by the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement [77]
and the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Statement [78].
We registered the protocol a priori on PROSPERO under CRD42016053482 (S1 Appendix).
Search
A manual search of the medical literature was performed in PubMed (MEDLINE), EMBASE,
Cochrane Trials, and Web of Science from inception until Dec 30, 2016, for relevant articles
that reported on mucosal recovery in celiac disease.
Mucosal recovery in celiac disease
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The PICO items of children-to-adults comparison were as follows: (P) celiac patients previ-
ously subjected to GFD with control biopsy, (I-C) adults and children, and (O) mucosal recovery
ratios.
We used the free-text terms “celiac disease”, “mucosal healing”, “mucosal recovery”, and “vil-
lous atrophy”. Our search strategy was developed by using text words related to celiac disease by
our review team of health care professionals and peer reviewed by an investigator with great
expertise in systemic review searching. For the draft of our search strategy, see S2 Appendix.
The search was limited to human and English language studies in PubMed and Embase, to
English language studies in Web of Science, but there were no filters imposed on the search in
Cochrane Trials. A recursive hand search in each reference list of relevant and included articles
was conducted to extend the coverage of the search.
PROSPERO, an international prospective register of systematic reviews, was hand searched
for ongoing and completed meta-analyses.
Selection and eligibility
The following publication types were excluded: letters, comments, conference abstracts, edito-
rials, and reviews.
We included both experimental (randomized or non-randomized, controlled or uncon-
trolled clinical trials) and observational studies (cohort, cross-sectional and case-control stud-
ies) carried out either in a prospective or a retrospective manner without respect to the
primary objectives of the studies. We excluded case reports and case series. The latest version
of updates was included. If there were multiple publications from the same register, the most
comprehensive report was included.
All the relevant articles were combined together in a reference manager software (EndNote
X8) to remove duplicates by searching overlaps between titles, abstracts, authors, and publica-
tion years.
After having duplicates removed, review authors screened the articles by title, abstract, and
full-texts against our pre-defined eligibility criteria. Each phase was carried out by two inde-
pendent investigators in duplicate, none of whom were blinded to publication data. Third
party arbitration resolved any discrepancies. We did not request any data from authors and
did not incorporate unpublished material.
To be eligible, celiac patients were supposed to be subjected to GFD prior to the control biopsy
which was staged by Marsh grades or any other histological classifications including only detailed
text description of the mucosal status that can be converted into Marsh grades with minimal risk
of bias [79–82]. Studies in which patients with childhood diagnosis (<18 years) were not separa-
ble from those with adulthood diagnosis (18 years) were excluded from the children-to-adults
comparison but included in other subgroups and/or meta-regressions, when appropriate.
GFD is defined as the dietary exclusion of gluten-containing cereals (i.e., wheat, barley, and
rye). The time elapsing between diagnostic and control biopsies is considered as the duration
of prescribed GFD if not stated otherwise.
There is no consensus on the terminology of mucosal histologic recovery (S1 Table). Fol-
lowing previous research, we defined complete mucosal recovery (primary outcome) as Marsh
0 [6, 7, 12, 13, 15, 25, 53] and disappearance of villous atrophy (secondary outcome) as any-
thing less than Marsh 3 (i.e., combined Marsh 0–2) [14, 22, 27, 39, 40, 45].
Quality assessment
The Newcastle-Ottawa Scale (NOS) tool [83], dedicated to assessing cohort studies, was
adjusted to the design of celiac studies (S2 Table). Items were assessed by one review author
Mucosal recovery in celiac disease
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blinded to the publication data. On this scale, a study is judged by items with points (stars in
the Newcastle-Ottawa Scale terminology) in three categories: selection of the study groups,
comparability of the groups, and outcome of interest. We removed the comparability items
due to the reasonable uncontrolled nature of celiac studies (i.e., endoscopic procedures would
carry an excessive risk for healthy controls), thereby studies could award one star for each.
Each item was rated as ‘high risk’ (equals to zero stars), ‘low risk’ (equals to one star), or
‘unclear risk’ (equals to zero stars) corresponding to the definitions (S2 Table). At the end, we
calculated the overall methodological quality of each study by adding the stars (a maximum of
six stars could be awarded). Overall quality scores were incorporated in the statistical analysis.
More than four scores indicated high methodological quality.
We used Grading of Recommendations Assessment, Development and Evaluation
(GRADE) [84] methodology for rating the quality of evidence as very low, low, moderate, or
high.
Studies recruiting patients on GFD before the control biopsy were labeled as prospective,
while all the other ones were considered as retrospective.
Data extraction
Data were extracted in duplicates by two independent investigators onto a standardized form
designed a priori. If needed, data were approximated from figures and graphs. Third party
arbitration resolved any discrepancies. Numeric and texted data were collected, as listed in S2
Appendix.
Statistical analysis
The statistical analysis was completed by a trained biostatistician expert (PM) by means of
Comprehensive Meta-analysis Software (Version 3, Biostat, Englewood) and Stata 11 SE (Stata
Corp). Recovery ratios were pooled using the random effects model with the DerSimonian-
Laird estimation and displayed on forest plots. Summary point estimations, 95% Confidence
Intervals (CIs), and 95% Predictive Intervals (PIs) were calculated from recovery ratios.
Statistical heterogeneity was tested using the I2 statistic adapting the thresholds of the
Cochrane Handbook of Systemic Reviews of Interventions: 0–40%, 30–60%, 50–90%, and 75–
100% indicated not important, moderate, substantial, and considerable heterogeneity [85].
Chi-square test was used for gaining probability-values (p<0.01 indicated significant heteroge-
neity) [86].
To explore heterogeneity, we performed subgroup analyses and univariate meta-regres-
sions. When different groups were compared, p<0.05 indicated a significant difference, while
we took 0.10>p0.05 as borderline significance. Comparisons of mucosal recovery ratios
were made as follows: (1) children to adults, (2) prospective to retrospective studies (3) patients
with strict GFD to those with non-strict or unknown adherence, (4) strict adherence to at least
12-month gluten-free diet to others, (5) patients followed up for 12 months to others, (6)
recovery ratios assessed by Marsh to Marsh-Oberhuber classification, different risk groups (by
S2 Table) concerning (7) dietary assessment, (8) duration of GFD, and (9) diagnostic histology;
the latter was performed only with the secondary outcome. In meta-regressions, the outcome
variable was Marsh 0 or 0–2 ratio; the explanatory variable was mean (first-preference) or
median of age on diagnosis in years or duration of GFD in months, initial Marsh 3 ratio, male
ratio, or methodological quality (overall quality score). We report the number of studies
included in the model, the regression coefficient, and the corresponding p-value on each
meta-regression where p<0.05 indicated a significant linear association.
Mucosal recovery in celiac disease
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Sensitivity analysis was used to assess the impact of high-risk studies by omitting them
from the analyses and recalculating to investigate their effects on the overall estimation.
The small-study effect was tested by the Egger’s test [87], p<0.05 indicated proof of bias.
Cohen’s was calculated for measuring agreement between the investigators in each phase
of selection. Values of kappa statistics can be interpreted, as follows:0 as declaring no agree-
ment, 0.01–0.20 as slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial,
and 0.81–1.00 as nearly perfect agreement [88].
Results
Fig 1 shows the flowchart of this meta-analysis. Our search strategy yielded 4452 studies of
which we selected 94 for full-text assessment and added another 21 from reference lists.
Finally, 61 studies met our inclusion criteria, none of them was a randomized-controlled trial
(Table 1, S3 Table) [4, 6–34, 36–55]. Only one [36] of six articles [36, 69, 70, 75, 89, 90] with
identical initial cohorts was included in full-text assessment (S4 Table). Not given the data on
recovery in ineligible formats, we excluded twelve articles [35, 91–101] after quality assess-
ment. Cohen’s was 0.78, 0.79, and 0.87 for selection by title, abstract, and full-text, respec-
tively; indicating at least substantial agreement between the investigators in each phase of
selection.
Pooled effects
Here, we pooled the histologic recovery ratios of small intestinal mucosa. The pooled complete
mucosal recovery ratio, calculated from 37 studies, was 0.36 (CI: 0.28–0.44, PI: -0.12–0.84; I2:
98.4%, p<0.01) (Fig 2). The pooled disappearance of villous atrophy ratio, calculated from 57
studies, was 0.64 (CI 0.58–0.70, PI: 0.23–1.05; I2: 97.5% p<0.01) (S1 File).
Subgroups and meta-regressions
Children showed higher control Marsh 0 ratio: 0.65 (CI: 0.44–0.85, PI: -0.10–1.39; I2: 96.5%,
p<0.01) vs. 0.24 (CI: 0.15–0.33, PI:-0.19–1.08; I2: 96.3%, p<0.01), p<0.01 (Fig 3). Similar dif-
ference with borderline significance was observed concerning the control Marsh 0–2 ratio (S1
File).
In the subgroup of strict dietary adherence, control Marsh 0 ratio was only 0.47 (S2 File)
and control Marsh 0–2 ratio was 0.72 (S1 File). We gained similar recovery ratios when we
included only patients with good dietary adherence and at least 12-month follow-up: 0.44 and
0.77 for control Marsh 0 and 0–2, respectively.
At the 12th month of gluten-free diet, only 38% (Fig 4) and 54% (S1 File) of patients
achieved complete mucosal recovery and disappearance of villous atrophy, respectively.
The control Marsh 0 and 0–2 ratios calculated by Marsh or Marsh-Oberhuber did not differ
significantly (p>0.10). Neither the study design (prospective vs. retrospective) nor the method
used for assessing dietary adherence affected the recovery ratios (p>0.10). Control Marsh 0–2
ratio was higher in studies including only patients with villous atrophy on diagnosis, as com-
pared to inclusion of patients with lesser histologic damage. However, the level of significance
was only borderline (p = 0.09).
I2 test showed considerable heterogeneity (except for the subgroup of patients with
12-month of diet with moderate heterogeneity), which proved to be significant in and across
the subgroups (p<0.01). Detailed results of the analyses are given in Table 2.
Age on diagnosis showed a significant negative linear correlation with control Marsh 0–2
ratio (p<0.01) but we observed only a tendency concerning Marsh 0 ratio (p = 0.05). Interest-
ingly, the duration of gluten-free diet did not affect recovery ratios (the correlation coefficient
Mucosal recovery in celiac disease
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was 0). Having omitted the studies with extreme length of follow-up from the analyses (more
than about 2 years of diet), we found a non-significant positive correlation (p = 0.13 and
Fig 1. Flow chart of assessment of studies identified in the meta-analysis.
https://doi.org/10.1371/journal.pone.0187526.g001
Mucosal recovery in celiac disease
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Table 1. Characteristics of the included studies. H: high quality, L: low quality, NR: not reported, P: prospective, R: retrospective.
Study Country Recruitment period Design Histological Classification
Annibale, 2001 [29] Italy 1994–1997 P Modified Marsh
Assiri, 2008 [44] Saudi Arabia 10 years R NR
Bannister, 2014 [45] Australia 2009–2011 R Marsh-Oberhuber
Bardella, 2007 [10] Italy NR R Marsh-Oberhuber
Baudon, 2005 [46] France 1971–1982 P NR
Bhasin, 2010 [15] India NR P Marsh
Biagi, 2012 [30] Italy 2008–2011 P After O’Mahony
Cammarota, 2007 [31] Italy 2004–2005 P Marsh-Oberhuber
Capristo, 2009 [56] Italy 1996–2007 P Marsh-Oberhuber
Carroccio, 2008 [20] Italy 2005–2006 P Marsh-Oberhuber
Caruso, 2014 [18] Italy 2011–2013 P Corazza-Vilanacci
Casella, 2012 [48] Italy 1990–2010 R Marsh-Oberhuber
Chaisemartin, 2015 [57] United Kingdom 2008–2012 R Marsh-Oberhuber
Ciacci, 2002 [11] Italy until 1997 R Marsh-Oberhuber
Ciacci, 2005 [47] Italy NR P NR
Congdon, 1981 [49] United Kingdom NR P Reported text description
Cuoco, 1998 [62] Italy 1993–1996 P Reported text description
Dickey, 2000 [21] United Kingdom 1996–1998 P Marsh-Rostami
Donaldson, 2008 [58] United States NR R Marsh-Oberhuber
Duerksen, 2010 [63] Canada NR P Modified Marsh
Elli, 2015 [23] Italy 2000–2012 R Marsh-Oberhuber
Galli, 2014 [6] Italy 2009–2012 P Marsh-Oberhuber
Ghazzawi, 2014 [50] United States 1997–2013 R Modified Marsh
Gorgun, 2009 [34] Belarus NR P Marsh
Gu¨nther, 2010 [59] Germany 2007–2009 P Marsh-Oberhuber
Hære, 2016 [22] Norway 1989–2009 R Marsh-Oberhuber
Hopper, 2008 [24] United Kingdom 2004–2006 P Marsh-Oberhuber
Hutchinson, 2010 [13] United Kingdom from 1971 R Modified Marsh
Karinen, 2006 [19] Finland NR P Reported text description
Kaukinen, 2002 [38] Finland NR P Marsh
Kemppainen, 1998 [52] Finland 1988–1990 P Reported text description
Koskinen, 2010 [60] Finland NR P Reported text description
Lanzini, 2009 [7] Italy from 1990 on R Marsh and Marsh-Oberhuber
Lebwohl, 2013 [36] Sweden 1969–2008 R Marsh
Lee, 2003 [5] United States NR R Reported text description
Lichtwark, 2014 [25] Australia NR P Marsh
Lidums, 2011 [39] Australia 2006–2009 P Marsh-Oberhuber
Martini, 2002 [53] Italy 2000–2001 P Marsh
McMillan, 2001 [26] United Kingdom NR P Marsh-Rostami
Newnham, 2016 [12] Australia NR P Marsh
O’Keeffe, 2001 [64] Ireland NR P NR
Pekki, 2015 [8] Finland 1996–2009 P Reported text description
Raivio, 2006 [65] Finland and Hungary NR P Reported text desciption
Rubio-Tapia, 2010 [9] United States until 2008 R Marsh-Oberhuber
Selby, 1999 [16] Australia 1994–1997 P Reported text description
Sharkey, 2013 [40] United Kingdom until 2012 R Marsh-Oberhuber
Shmerling, 1986 [41] Switzerland 1960–1983 R After Shmerling
(Continued )
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p = 0.18 for control Marsh 0 and 0–2 ratios, respectively). Diagnostic Marsh 3 ratio was closely
associated with control Marsh 0 and 0–2 ratios (p<0.01), here we observed a strong negative
linear correlation (coefficient: -8.97 and -12.09 for control Marsh 0 and 0–2 ratios, respectively.
Male sex ratio was clearly associated with higher control Marsh 0 ratio (p<0.01) but not with
control Marsh 0–2 (p = 0.87). Detailed results and figures of the analyses are given in Table 3
and in S3 File, respectively.
Quality of evidence
This meta-analysis included observational studies of which 21 (34%) were retrospective and
most of them were uncontrolled (S5 Table). We rated the quality of evidence as very low due
to risk of bias, inconsistency and the high number of uncontrolled studies.
Sensitivity analysis
The removal of high-risk articles [13, 36] did not influence statistical significance.
Small-study effect
We could not prove the presence of small-study effect (p = 0.93 and p = 0.11 for pooled control
Marsh 0 and 0–2 outcomes, respectively) (S4 File).
Discussion
Here, we aimed to investigate histologic recovery ratios of small intestinal mucosa in celiac
patients subjected to GFD, with special emphasis on the modifying effect of age on diagno-
sis. Our findings are consistent with the previous meta-analysis, where persistent villous
atrophy was detectable in about one third (38%) of the celiac population and children
tended to have lower atrophy ratios (19%), as compared to adults (38%) [74]. Here, we con-
firmed that persistent villous atrophy ratio is inexplicably common in treated celiac patients
(in about one third of the patients), so are persistent mucosal abnormalities (in about two
third of the patients). Consequently, two third of the patients had intact villous architecture
(S1 File) and one third of them achieved complete mucosal recovery (Fig 2). We also found
that childhood diagnosis was closely associated with higher complete recovery ratios (65%
Table 1. (Continued)
Study Country Recruitment period Design Histological Classification
Sjo¨berg, 2014 [66] Sweden 1998–2002 R Marsh
Tuire, 2012 [37] Finland NR P Marsh
Tursi, 2006 [42] Italy 2001–2004 P Marsh
Uil, 1996 [54] The Netherlands NR P Reported text description
Vahedi, 2003 [17] France 1994–1999 P Marsh-Oberhuber
Valdimarsson, 2000 [55] Sweden 1989–1997 P Alexander
Ve´csei, 2009 [28] Austria 1989–2006 R Marsh-Oberhuber
Ve´csei, 2014 [51] Austria 2009–2010 P Marsh-Oberhuber
Vivas, 2009 [27] Spain 2000–2008 P Marsh-Oberhuber
Volta, 2008 [67] Italy 2005–2006 P Marsh-Oberhuber
Wahab, 2001 [61] The Netherlands NR P Marsh-Rostami
Wahab, 2002 [14] The Netherlands 1985–2000 R Marsh
Yachha, 2007 [43] India 1991–1999 P Marsh
Zanini, 2012 [68] Italy 2001–2010 R Marsh
https://doi.org/10.1371/journal.pone.0187526.t001
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Fig 2. Forest plot: Complete mucosal recovery ratios of each study included.
https://doi.org/10.1371/journal.pone.0187526.g002
Mucosal recovery in celiac disease
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vs. 24% and 74% vs. 58% for complete recovery (Fig 3) and disappearance of villous atrophy
(S1 File)). The favorable impact of early age at diagnosis was also confirmed with regression
analysis (Table 3 and S3 File).
As we expected, statistics revealed considerable heterogeneity and consequent wide predic-
tive intervals (Table 2), which reflects differences in study settings, baseline characteristics, fol-
low-up times, dietary adherence, and methodology (S6 and S7 Tables).
Fig 3. Forest plot: Complete mucosal recovery ratios of children-to-adults comparison.
https://doi.org/10.1371/journal.pone.0187526.g003
Mucosal recovery in celiac disease
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The exploration of heterogeneity
Besides good dietary adherence [6, 7, 9, 11, 13, 33], other modifiers of mucosal recovery are
less clear. Poor adherence can be the cause of persistent symptoms [6]; furthermore, lack of
GFD leads to increased mortality [102, 103]. However, poor adherence cannot explain the low
recovery ratios itself and good adherence cannot guarantee high ratios [9]. Our results are in
line with this finding: only 47% of strictly adherent patients achieved complete mucosal recov-
ery (S2 File) and 72% had intact villi (S1 File). Recovery ratios might have been underestimated
due to short follow-up; however, including only studies with at least 12-month of gluten-free
diet did not improve the recovery ratios considerably (±5%) (Table 2). Interestingly, less than
50% of patients achieved complete mucosal recovery in seven studies with good adherence
[12, 20, 21, 25, 37, 38, 43] in two studies [20, 43], complete recovery (i.e., Marsh 0) was not
achieved almost at all, as well as disappearance of villous atrophy ratio (i.e., Marsh 0–2) was
surprisingly low in three studies [20, 21, 43]. In one cohort including only children [43], 5
years of strict GFD was not enough to achieve Marsh 0 but it was enough to downgrade the
histologic damage to Marsh 1–2. Here we question the strictness of the diet; besides, infections,
Fig 4. Forest plot: Complete mucosal recovery ratios of patients after 12-month gluten-free diet.
https://doi.org/10.1371/journal.pone.0187526.g004
Mucosal recovery in celiac disease
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delayed diagnosis, and genetic background are hypothesized as impeding factors of recovery.
Similarly, another author [21] could not show higher than 40% of complete recovery ratio
within 12-month follow-up, despite good adherence. In one study [20], poor recovery ratios
might be explained by selection bias: patients with refractory gastrointestinal symptoms com-
prised the majority of the study population. Turning to the other end of the spectrum, almost
every patient (>90%) reached complete recovery on a strict diet [11]. Although it was a long
follow-up study (2–22 years), they could not establish a significant correlation between the
duration of follow-up and mucosal recovery. Despite the high recovery ratio, a negative corre-
lation existed between the follow-up time and the dietary adherence [11].
In children diagnosed over four years of age, dietary adherence dropped [104] while the
recovery ratio might have dropped in parallel with it although separate data on children are
not available [30]. Consequently, it seems reasonable to belive that the earlier celiac disease is
diagnosed, the better recovery ratio can be achieved in the long run. It is possible that this
drop in dietary adherence with aging is responsible for the observed negative correlation
between recovery ratios and age on diagnosis. In adults, literature results are nearly consistent:
a strong correlation between the ratio of incomplete recovery and poor adherence was fre-
quently detected [6, 8, 9, 11–13, 17, 33]. As to the cause of various recovery ratios, we cannot
Table 2. Results of subgroup analyses.
p Recovery ratios Number of studies
(n)
I2 across
groups
Complete mucosal recovery
Children vs. adults <0.01* 0.65 (0.44–0.85) vs. 0.24 (0.15–0.33) 7 vs. 8 99.0%
Strict vs. non-strict/uncertain gluten-free diet 0.39 0.47 (0.24–0.70) vs. 0.33 (0.23–0.45) 12 vs. 26 95.6%
Strict adherence with at least 12-month gluten-free diet
vs. others
0.32 0.44 (0.26–0.64) vs. 0.33 (0.23–0.44) 10 vs. 27 95.7%
Patients followed up for 12 months vs. others 0.70 0.38 (0.28–0.48) vs. 0.36 (0.27–0.45) 7 vs. 30 98.3%
Length of gluten-free diet
(high vs. low risk)
0.91 0.34 (0.20–0.52) vs. 0.33 (0.24–0.44) 10 vs. 27 95.0%
Assessment of adherence
(high vs. low vs. uncertain risk)
0.25 0.62 (0.27–0.88) vs. 0.33 (0.23–0.44) vs. 0.29
(0.17–0.45)
3 vs. 22 vs. 12 95.1%
Marsh vs. Marsh-Oberhuber classification 0.76 0.31 (0.18–0.47) vs. 0.34 (0.22–0.47) 13 vs. 18 95.7%
Prospective vs. retrospective design 0.86 0.34 (0.23–0.48) vs. 0.33 (0.20–0.47) 19 vs. 14 95.4%
Disappearance of villous atrophy
Children vs. adults 0.05# 0.74 (0.57–0.90) vs. 0.58 (0.45–0.71) 11 vs. 10 96.5%
Strict vs. non-strict/uncertain gluten-free diet 0.06# 0.72 (0.60–0.84) vs. 0.66 (0.59–0.72) 17 vs. 40 92.8%
Strict adherence with at least 12-month gluten-free diet
vs. others
0.08# 0.77 (0.67–0.85) vs. 0.66 (0.60–0.72) 14 vs. 43 92.9%
Patients followed up for 12 months vs. others 0.03* 0.54 (0.41–0.67) vs. 0.67 (0.60–0.73) 12 vs. 45 97.5%
Length of gluten-free diet
(high vs. low vs. uncertain risk)
0.68 0.70 (0.56–0.81) vs. 0.65 (0.59–0.71) vs. 0.58
(0.34–0.79)
10 vs. 44 vs. 3 92.9%
Assessment of adherence
(high vs. low vs. uncertain risk)
0.60 0.59 (0.33–0.81) vs. 0.64 (0.56–0.71) vs. 0.69
(0.60–0.76)
4 vs. 27 vs. 26 92.9%
Initial histology
(high vs. low vs. uncertain risk)
0.09# 0.73 (0.64–0.80) vs. 0.61 (0.54–0.65) vs. 0.70
(0.58–0.80)
12 vs. 32 vs. 9 92.9%
Marsh vs. Marsh-Oberhuber classification 0.39 0.71 (0.59–0.81) vs. 0.65 (0.55–0.73) 12 vs. 21 94.6%
Prospective vs. retrospective design 0.13 0.63 (0.56;0.70) vs. 0.72 (0.63–0.79) 36 vs. 17 92.9%
* indicates statistical significance (p<0.05).
# indicates borderline significance (0.10>p0.05).
https://doi.org/10.1371/journal.pone.0187526.t002
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rule out inadvertent gluten ingestion, even in those who adhered to a strict GFD [105, 106] but
persisting atrophy is unlikely to be the consequence of mild dietary transgressions (Codex-
GFD) [16]. Foods containing trace amounts of gluten (<50 mg/day, i.e., occult sources or glu-
ten contamination) are considered relatively safe [32]. Intraepithelial lymphocytosis reduction
—and especially that of γδ T-cells—requires a longer period of time without dietary transgres-
sions as compared to the resolution of villous atrophy [107, 108] and might contribute to the
unexpectedly low control Marsh 0 ratios (Fig 2).
The beneficial effect of early age on diagnosis is a matter of controversy. In general, children
tend to recover faster than adults [10, 14, 15]. Young age on diagnosis (i.e. an early diagnosis)
was found an independent predictor of recovery [10], while other findings did not confirm
this [6–8, 12]. Each year delay in the diagnosis results in an extra 1.106 odds ratio of having
persisting duodenal abnormalities (2.751 odds ratio for 10 years) [10]. We confirmed an
inverse correlation between the age on diagnosis (under 50 years) and control Marsh 0–2 ratio
in regression analysis (p<0.01) and a tendency with control Marsh 0 (p = 0.05) (S3 File).
Again, better adherence in childhood can be a reasonable confounding factor [104]. The corre-
lation might reflect the cumulative (lifetime) gluten exposure, but in general, the duration of
gluten exposure is proportional to age on diagnosis and to the disease duration, consequently.
Taken together, the earlier the diagnosis is made the higher the chance of achieving complete
mucosal recovery thereby avoiding the sequelae of persisting damage.
According to the American College of Gastroenterology (2013), control biopsies should be
taken after 2 years of GFD from adults and not routinely from children in order to assess
mucosal recovery [72]. Nevertheless, long-term follow-up studies of high quality are lacking.
We do not assume a positive correlation between duration of GFD and recovery ratios, not
even within about two years of diet (S3 File). We could separate neither children from adults
nor patients with different dietary adherence in regression analysis due to the low amount of
corresponding data. These findings are in accordance with a previous study, where the length
of GFD did not predict mucosal recovery in the long run (2–22 years) [11]. Lack of correlation
might imply no further (or just negligible) improvement in mucosal status. Therefore, taking
Table 3. Detailed results of meta-regressions.
p Coefficient Number of studies
Complete mucosal recovery
Age at diagnosis 0.05# -0.03 18
Length of gluten-free diet 0.62 0.01 21
Length of gluten-free diet (9–26.4 months) 0.13 0.09 16
Diagnostic Marsh 3 ratio <0.01* -8.97 17
Male ratio <0.01* 6.04 29
Quality 0.08# 0.28 33
Disappearance of villous atrophy
Age at diagnosis <0.01* -0.03 24
Length of gluten-free diet 0.86 0.00 33
Length of gluten-free diet (9–27 months) 0.18 0.04 17
Diagnostic Marsh 3 ratio <0.01* -12.09 17
Male ratio 0.87 0.24 42
Quality 0.85 0.02 53
* indicates statistical significance (p<0.05).
# indicates borderline significance (0.10>p0.05).
https://doi.org/10.1371/journal.pone.0187526.t003
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control biopsy from symptomless patients repeatedly seems to be unnecessary because intesti-
nal mucosa might not tend to change in the long run. As a matter of fact, the present analysis
suffers from the limitation that we did not have data about mucosal status within 9 months of
gluten-free diet which might be the critical period of the development of mucosal recovery.
The 12th month of the diet is a widely accepted time point to assess mucosal recovery.
Although control Marsh 0 ratio is similar to the pooled effect (Fig 4), control Marsh 0–2 ratio
seems to be lower (S1 File), suggesting further recovery. Control biopsy should be scheduled
for later than this time point to improve the identification rate of those with true persistent vil-
lous atrophy.
Theoretically, it is plausible that the speed of recovery varies among people hence it is hard
to distinguish those with slow, gradual improvement from those with persisting damage with-
out taking repeated samples. Initial presentation, such as classical celiac disease [109] or mal-
absorption [8], might require longer time to recover, probably due to more severe initial
damage. It is also possible that mucosal recovery occurs periodically in accordance with the
intensity of the spontaneous or gluten-triggered local inflammation. The mucosal expression
of genes activated in Th1 response (e.g., STAT1, IRF1), remained still enhanced, and was
accompanied by a suppressed Th2 response, after 1 year of GFD [110]. Low recovery ratios
(despite a long, strict GFD) might be explained by this gluten-independent immune dysregula-
tion and persisting inflammation.
The assumption that more severe initial histology permits less/slower histological response
is well supported by a large body of evidence [6–9, 13–15, 69]. Three studies [6, 7, 69] found
initial histological severity an independent predictor of recovery, and only two studies [11, 12]
did not support this. Our results are congruent with the general opinion: the initial Marsh 3
ratio correlates inversely with the frequency of control Marsh 0 and 0–2 ratios (S3 File). Here,
the possible confounding effect of age and dietary adherence was not taken into account.
Male gender seems to be a predictor of mucosal recovery. The positive correlation was sig-
nificant in terms of control Marsh 0 (S3 File). Most previous research considered the gender
neutral [6–11, 13, 23], while two studies found it as an independent predictor recovery [7, 12].
Our results opposed the largest cohort so far [69] where female gender was associated with
mucosal recovery. Gender-dependent difference in dietary adherence is unlikely to be a con-
founding factor since males proved to be as adherent as females earlier [111].
As a matter of fact, the items of the adapted Newcastle-Ottawa Scale did not cover the entire
sampling, processing, and evaluating procedure. In addition, detailed descriptions of sampling
methods were scarce in our material: half of the studies included did not publish sufficient
information about the endoscopic procedure, biopsy sampling, and histological preparations.
Furthermore, methodological discrepancies were common and likely to contribute to the con-
siderable heterogeneity (S6 and S7 Tables).
Prognostic role of mucosal recovery
Although persisting intestinal damage often co-occurs with higher frequency of comorbidities
(e.g., metabolic osteopathy [8, 70, 73, 76] or malignancies [9, 73, 75]), recent evidence suggests
that lack of mucosal recovery is not associated with higher mortality in the long run [8, 36].
Strengths and limitations
The main strength of this meta-analysis is its comprehensiveness. Although we faced signifi-
cant heterogeneity, various possible sources were explored, which resulted in convincing
explanations. Despite the low case numbers of the individual studies, we could not prove sig-
nificant small-study effect. The funnel plots are symmetric (S4 File). The methodological
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quality of the studies included was rigorously assessed (S2 and S5 Tables) and incorporated in
the synthesis (Table 3).
It has to be mentioned that only observational studies fulfilled our eligibility criteria: to
date, no randomized-controlled study has been published focusing on mucosal recovery.
Although uncontrolled, retrospective study design was common, the comparison of prospec-
tive and retrospective studies did not yield a significant difference (Table 2). The quality of evi-
dence (GRADE) was rated very low for both outcomes [84]; however, low quality is inherent
in meta-analysis of observational studies [85].
Alternative variables falling outside the scope of this piece of work should be contemplated:
e.g., study setting, various endoscopic and sampling protocols, difference in sample prepara-
tion or in the fashion of histological assessment. All of these factors might contribute to hetero-
geneity (S6 Table). So does genetic background: although one study [19] reported a correlation
between HLA-DQ2 gene dose and recovery ratios, this was not confirmed later [7]. The effects
of other loci on histological recovery are unknown. The presence of Helicobacter pylori infec-
tion is unlikely to impede mucosal recovery but might be the cause of persisting intraepithelial
lymphocytosis [7, 10]. Higher levels of patients’ background knowledge associated with the
better histological response can also be a confounding factor [11, 69].
The dietary interview carried out by a trained interviewer has still remained the best tool: it
predicts the persisting damage with proper accuracy. Discrepancies in dietary assessment
across studies were tremendous, many did not even report on how they assessed GFD, raising
doubts about the true dietary adherence (S7 Table). We must mention that there is an urgent
need for the development of an accurate and objective method to assess true dietary adherence.
Based on the results of the last decades, the pervasive celiac-specific serology exhibited low
specificity in detecting persisting mucosal damage [74]. Short diet can distort the results, but
the recovery ratios of the studies including patients with a GFD shorter than 1 year did not dif-
fer significantly from the longer ones (Table 2).
The inclusion of those not having villous atrophy on diagnosis might distort the calcula-
tions of Marsh 0–2 outcome (the outcome might be present before the diet). We dismissed
this hypothesis because the recovery ratio proved to be even higher in the subgroup of high-
risk studies, as compared to low-risk ones (Table 2).
Conversion of histological classifications into Marsh grades can lead to mild distortions in
the set of data [112]. The cut-off between normal and pathological intraepithelial lymphocyto-
sis ranges between 25 and 40 per 100 enterocytes [80–82] in between the change of the cut-off
does hardly introduce bias [7]. We could not detect significant difference between the recovery
rates graded by Marsh or Marsh-Oberhuber classification (Table 2).
Non-English language articles were excluded due to the lack of resources available to trans-
late articles, raising the possibility of missing relevant articles.
Data on age and duration of GFD were given as mean and/or median due to inconsistent
follow-up periods. Having assumed these values to be representative of the initial sample, we
used them as explanatory variables in meta-regressions.
Conclusions
Despite the prescribed GFD, we found unexpectedly low complete mucosal recovery ratios
(36%), even in patients being on a strict diet (47%). Disappearance of villous atrophy was more
frequent (64%) than complete recovery, but far from 100% even in those following a strict diet
(72%). These numbers emphasize the importance of performing a control biopsy in celiac
patients to detect persisting histologic damage predisposing to several adverse outcomes (e.g.,
osteoporosis, malignancies).
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In a 12-month gluten-free diet, 38% and 54% of patients exhibited complete mucosal recov-
ery and disappearance of villous atrophy, respectively. However, one year of diet might be
insufficient to achieve mucosal recovery therefore biopsies should be taken later.
Children show higher complete recovery (65%) and disappearance of villous atrophy
ratios (74%) as compared to adults (24% and 58%, respectively), which was supported with
regression analysis. Early diagnosis (therefore early initiation of the diet) can lead to higher
mucosal recovery ratios; consequently, early diagnosis might help to reduce the frequency
of adverse outcomes in the long run. This conclusion should be confirmed by prospective
studies.
We could not confirm the positive correlation between the length of GFD and mucosal
recovery ratios either in the long run or between 9 months and about 2 years of diet. Accord-
ingly, repeated control biopsies should not be taken from asymptomatic patients compliant
with the diet to monitor mucosal recovery because results do not imply further histological
improvement after several years of GFD.
Regression analysis revealed that more severe diagnostic histologic damage and female gen-
der is closely associated with low mucosal recovery ratios. These risk groups might require
stricter follow-up and GFD.
Given the considerable heterogeneity of the included studies, we would like to encourage
the authors to follow the standard endoscopic and histologic procedures when conducting
research in the field.
Our results might contribute to the identification of those subjects who would benefit from
a control biopsy. Well-designed, controlled studies with large sample size are needed to vali-
date our findings and discover further associations.
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